



MATERIAL SAFETY DATA SHEET

While we believe the information provided herein is accurate and current, Monarch Pharmaceuticals, Inc. makes no representations or warranties, either expressed or implied, and assumes no responsibility for any damage or injuries of any kind, which may result from use or reliance upon this information.

SECTION I	IDENTIFICATION
------------------	-----------------------

PRODUCT NAME: Neosporin® Products **DATE OF ISSUE:** 08/12/98

CAS#: NA **REVISED:** 05/15/07

FORMULA: Mixture

Contact Information: King Pharmaceuticals, Inc.	Address: 501 Fifth Street Bristol TN 37620	Phone: 1-800-776-3637
---	---	---------------------------------

SECTION II	INGREDIENTS
-------------------	--------------------

EXPOSURE LIMITS/GUIDELINES

CAS#	INGREDIENT NAME	OSHA PEL	ACGIH TLV	OTHER	LISTED AS CARCINOGEN
1405-20-5	Polymyxin B Sulfate	ND	ND	ND	NO
1405-10-3	Neomycin Sulfate	ND	ND	ND	NO
1405-87-4	Bacitracin Zinc	ND	ND	ND	NO
137-58-6	Lidocaine	ND	ND	ND	NO

Note: Refer to specific product labeling or insert to determine which of the above ingredients are present. Specific ingredient hazards are included in the MDS.

SECTION III	PHYSICAL DATA
--------------------	----------------------

BOILING POINT: NA	VAPOR PRESSURE: ND
VAPOR DENSITY: NA	SOLUBILITY IN WATER: ND
SPECIFIC GRAVITY: (H ₂ O=1): ND	% VOLATILE BY VOLUME: ND
EVAPORATION RATE: ND	MELTING POINT: ND

DESCRIPTION: Refer to product label/insert for specific product description.

SECTION IV	FIRE AND EXPLOSION DATA
-------------------	--------------------------------

FLASH POINT AND METHOD: ND

FLAMMABLE LIMITS: LEL: ND UEL: ND

SPECIAL FIRE FIGHTING PROCEDURES: Self-contained breathing apparatus

UNUSUAL FIRE AND EXPLOSION HAZARDS: May emit toxic or irritant fumes when heated.

EXTINGUISHING MEDIA: Use agent appropriate to the nature of the fire and other materials involved.

SECTION V**HEALTH HAZARD DATA**

TOXICITY INFORMATION: This information pertains to the active ingredient. Emphasis should be placed on the potential effects that may occur with the occupational handling (by inhalation, dermal, or ocular contact) of the product.

Polymyxin B Sulfate: Neurotoxicity, nephrotoxicity, and neuromuscular blockade are the characteristic results of systemic polymyxin poisoning. Fever has also been reported. Repeated or prolonged exposure by ingestion may cause kidney damage. In view of the nonabsorbability of this antibiotic it does not present an oral hazard unless the gut is diseased. Hygienic precautions should anticipate possibility of sensitization. IV-mouse LD₅₀: 5.4 mg/kg; IV-Dog LD_{LO}: 8 mg/kg; oral-mouse LD₅₀: 790 mg/kg; IP-mouse LD₅₀: 20.5 mg/kg; dermal subcutaneous-mouse LD₅₀: 59.5 mg/kg

Neomycin Sulfate: Hypersensitivity reactions (primarily skin rashes) have occurred in persons treated with neomycin sulfate. May cause severe renal (kidney) toxicity and neurotoxicity including ototoxicity (hearing loss and diminished balance) when administered parenterally (IV). Neuromuscular blockade and respiratory paralysis have also occurred in rare cases. Oral-rat LD₅₀: >4325 mg/kg; IV-mouse LD₅₀: 17.4-150 mg/kg

Bacitracin Zinc: May cause irritation. Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals. Nephrotoxicity (kidney toxicity) results after extended use at high levels. Because it is not absorbed from the gastrointestinal tract accidental ingestion it presents no toxic hazard. Oral-rat LD₅₀: >2000 mg/kg

Lidocaine: Possible eye, skin and/or respiratory tract irritant. May cause topical anesthesia. Ingestion is toxic. Oral-rat LD₅₀: 317 mg/kg

Refer to labeling, insert, or Physicians' Desk Reference for further information.

Emergency and First Aid Procedures:

Eyes:	Rinse immediately with plenty of water. Contact physician.
Inhalation:	Remove person to fresh air, rest and keep warm. Use artificial respiration if breathing stops. Contact physician.
Ingestion:	Wash out mouth. Give plenty of water or bland fluids. Unless vomiting is copious, lavage should be carried out. Contact physician.
Skin:	Remove all contaminated clothing. Wash off skin with plenty of water. Contact physician if contact produces irritation.

SECTION VI**REACTIVITY DATA**

STABILITY: Stable

INCOMPATIBILITY (MATERIALS TO AVOID): None known

CONDITONS TO AVOID: None known

HAZARDOUS POLYMERIZATION: None known

HAZARDOUS POLYMERIZATION: None known

SECTION VII**SPILL OR LEAK PROCEDURES**

STEPS TO BE TAKEN IF MATERIAL IS SPILLED OR LEAKED: Wipe or mop up spilled material. Wash all contaminated surfaces with soap and water. Place waste in appropriate container for disposal.

WASTE DISPOSAL METHOD: Comply with state and local regulations regarding disposal of medicinal waste.

SECTION VIII**SPECIAL PROTECTION INFORMATION**

RESPIRATORY PROTECTION: None necessary.

EYE PROTECTION: Avoid eye contact.

PROTECTIVE GLOVES: Latex

VENTILATION: None necessary

OTHER PROTECTIVE EQUIPMENT: NA

SECTION IX**SPECIAL PRECAUTIONS**

PRECAUTIONS TO BE TAKEN IN HANDLING AND STORAGE: Store in original container tightly closed.

OTHER PRECAUTIONS: Avoid skin and eye contact. Should such contact occur wash exposed area promptly.

SECTION X**REFERENCES**

Physicians Desk Reference, 52nd Ed., Medical Economics Co., Inc. Montvale, NJ 1998

NA = Not Applicable

ND = Not Determined

The information provided in this Material Safety Data Sheet has been compiled from our experience and the data presented in various technical publications. It is the user's responsibility to determine the suitability of this information for the adoption of safety precautions as may be necessary. We reserve the right to revise the Material Safety Data Sheets from time to time as new information becomes available. The user has the responsibility to contact the company to make sure the sheet is the latest one issued.